PacBio Outlines Expected Commercial Performance for RS at AGBT as Users Talk About their Experience

At a conference workshop, PacBio reported on the performance of its system in seven early-access customer labs and said how it expects the instrument to perform at commercial launch in the second quarter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.